1-t-butoxycarbonyl-4-(3-ethyl-1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)piperidine | 87120-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-t-butoxycarbonyl-4-(3-ethyl-1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)piperidine
• 英文别名: Tert-butyl 4-(3-ethyl-2-oxobenzimidazol-1-yl)piperidine-1-carboxylate
• CAS: 87120-84-1
• 化学式: C₁₉H₂₇N₃O₃
• 分子量: 345.442
• InChiKey: OVYFFIHKVRZNME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  53.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-t-butoxycarbonyl-4-(3-ethyl-1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)piperidine 在 三氟乙酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 以0.84 g的产率得到1-ethyl-3-piperidine-4-yl-1,3-dihydrobenzoimidazol-2-one
  参考文献：
  名称：

  Structure–activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide

  摘要：

  Twelve derivatives of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP) antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide (Comp 24) were synthesised and tested in binding experiments performed on CHOhNOP cell membranes. Among them, a novel interesting NOP receptor antagonist (compound 35) was identified by blending chemical moieties taken from different NOP receptor ligands. In vitro in various assays, Compound 35 consistently behaved as a pure, highly potent (pA(2) in the range 8.0-9.9), competitive and NOP selective antagonist. However compound 35 was found inactive when challenged against N/OFQ in vivo in the mouse tail withdrawal assay. Thus the usefulness of the novel NOP ligand compound 35 is limited to in vitro investigations. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.068
• 作为产物：
  描述：

  4-（2-酮酸-1-苯并咪唑）哌啶 在 sodium hydride 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 14.0h， 生成 1-t-butoxycarbonyl-4-(3-ethyl-1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)piperidine
  参考文献：
  名称：

  （1-取代的哌啶-4-基）-1 H-苯并咪唑和（1-取代的哌啶-4-基）-3,4-二氢喹唑啉的合成作为可能的降压药

  摘要：

  通过用其他杂环（2-氰基氨基，2-乙氧基和2-甲基苯并咪唑和2-氰基氨基-3,4-二氢喹唑啉）取代苯并咪唑啉酮基团，对4-哌啶基苯并咪唑啉酮类（I）进行结构修饰，并且已经制备了许多新的哌啶（II）被合成为潜在的降压药。

  DOI：

  10.1002/jhet.5570200315

文献信息

• OBASE, HIROYUKI;TAKAI, HARUKI;TERANISHI, MASAYUKI;NAKAMIZO, NOBUHIRO, J. HETEROCYCL. CHEM., 1983, 20, N 3, 565-573
  作者：OBASE, HIROYUKI、TAKAI, HARUKI、TERANISHI, MASAYUKI、NAKAMIZO, NOBUHIRO

  DOI：——

  日期：——
• Synthesis of (1-substituted piperidin-4-yl)-1<i>H</i>-benzimidazoles and (1-substituted piperidin-4-yl)-3,4-dihydroquinazolines as possible antihypertensive agents
  作者：Hiroyuki Obase、Haruki Takai、Masayuki Teranishi、Nobuhiro Nakamizo

  DOI：10.1002/jhet.5570200315

  日期：1983.5

  other heterocycles (2-cyanoamino, 2-ethoxy, and 2-methylbenzimidazole and 2-cyanoamino-3,4-dihydroquinazoline) has been made and a number of new piperidines (II) were synthesized as potential antihypertensive agents.

  通过用其他杂环（2-氰基氨基，2-乙氧基和2-甲基苯并咪唑和2-氰基氨基-3,4-二氢喹唑啉）取代苯并咪唑啉酮基团，对4-哌啶基苯并咪唑啉酮类（I）进行结构修饰，并且已经制备了许多新的哌啶（II）被合成为潜在的降压药。
• Structure–activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide
  作者：Claudio Trapella、Carmela Fischetti、Michela Pela’、Ilaria Lazzari、Remo Guerrini、Girolamo Calo’、Anna Rizzi、Valeria Camarda、David G. Lambert、John McDonald、Domenico Regoli、Severo Salvadori

  DOI：10.1016/j.bmc.2009.05.068

  日期：2009.7

  Twelve derivatives of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP) antagonist 1-benzyl-N-3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide (Comp 24) were synthesised and tested in binding experiments performed on CHOhNOP cell membranes. Among them, a novel interesting NOP receptor antagonist (compound 35) was identified by blending chemical moieties taken from different NOP receptor ligands. In vitro in various assays, Compound 35 consistently behaved as a pure, highly potent (pA(2) in the range 8.0-9.9), competitive and NOP selective antagonist. However compound 35 was found inactive when challenged against N/OFQ in vivo in the mouse tail withdrawal assay. Thus the usefulness of the novel NOP ligand compound 35 is limited to in vitro investigations. (C) 2009 Elsevier Ltd. All rights reserved.